438 related articles for article (PubMed ID: 15389273)
21. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
22. Anti-TNF-alpha therapy for sight threatening uveitis.
Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
[TBL] [Abstract][Full Text] [Related]
23. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
[TBL] [Abstract][Full Text] [Related]
24. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions.
Adán A; Hernandez V; Ortiz S; Molina JJ; Pelegrin L; Espinosa G; Sanmartí R
Int Ophthalmol; 2010 Oct; 30(5):577-81. PubMed ID: 20490893
[TBL] [Abstract][Full Text] [Related]
25. Retrospective case review of pediatric patients with uveitis treated with infliximab.
Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
[TBL] [Abstract][Full Text] [Related]
26. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.
Petropoulos IK; Vaudaux JD; Guex-Crosier Y
Klin Monbl Augenheilkd; 2008 May; 225(5):457-61. PubMed ID: 18454398
[TBL] [Abstract][Full Text] [Related]
27. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
[TBL] [Abstract][Full Text] [Related]
28. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial.
Korhonen T; Karppinen J; Paimela L; Malmivaara A; Lindgren KA; Bowman C; Hammond A; Kirkham B; Järvinen S; Niinimäki J; Veeger N; Haapea M; Torkki M; Tervonen O; Seitsalo S; Hurri H
Spine (Phila Pa 1976); 2006 Nov; 31(24):2759-66. PubMed ID: 17108825
[TBL] [Abstract][Full Text] [Related]
29. Infliximab for chronic cystoid macular edema associated with uveitis.
Markomichelakis NN; Theodossiadis PG; Pantelia E; Papaefthimiou S; Theodossiadis GP; Sfikakis PP
Am J Ophthalmol; 2004 Oct; 138(4):648-50. PubMed ID: 15488796
[TBL] [Abstract][Full Text] [Related]
30. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
[TBL] [Abstract][Full Text] [Related]
31. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
32. [The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept].
Zhang MF; Zhao C; Wen X; Du H; Zhao Y
Zhonghua Yan Ke Za Zhi; 2010 Feb; 46(2):145-50. PubMed ID: 20388349
[TBL] [Abstract][Full Text] [Related]
33. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
34. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha.
Evereklioglu C; Borlu M
Br J Ophthalmol; 2008 Aug; 92(8):1034, 1148-9. PubMed ID: 18653594
[No Abstract] [Full Text] [Related]
35. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
[TBL] [Abstract][Full Text] [Related]
36. Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up.
Odorcic S; Keystone EC; Ma JJ
Cornea; 2009 Jan; 28(1):89-92. PubMed ID: 19092414
[TBL] [Abstract][Full Text] [Related]
37. Vitreous surgery in the management of chronic endogenous posterior uveitis.
Scott RA; Haynes RJ; Orr GM; Cooling RJ; Pavésio CE; Charteris DG
Eye (Lond); 2003 Mar; 17(2):221-7. PubMed ID: 12640410
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.
Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW;
Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
